On 20 September 2010, orphan designation (EU/3/10/779) was granted by the European Commission to Cancer Prevention Pharma Ltd, United Kingdom, for eflornithine for the treatment of familial adenomatous polyposis.
The sponsorship was transferred to Cancer Prevention Pharma (Ireland) Limited. Ireland, in April 2019.
|Disease / condition||
Treatment of familial adenomatous polyposis (FAP)
|Date of first decision||
|EU designation number||
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;